Clinical Trial Update: GPPAD-POInT (Global Platform of Autoimmune Diabetes - Primary Oral Insulin Trial) [Phase 2]

View source ↗

Summary

Phase 2 trial GPPAD-POInT evaluated primary prevention of Type 1 diabetes using oral insulin and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Oral insulin (insulin)

Snippet

Sponsor: Technical University of Munich | Conditions: Diabetes Mellitus, Type 1 | Phase 2 | Status: COMPLETED